 |
|
Anti-clotting drug thins risk to pregnancy and surgery patients with blood disorder
December 09, 2008Pregnancy and surgery patients with a serious blood disorder that causes excessive clotting have responded well to treatment with a man-made anti-clotting protein. Results from a study by researchers at Yale School of Medicine and other institutions were presented December 6 at the Annual Meeting of the American Society of Hematology (ASH) in San Francisco.
The phase III, multi-center clinical trial focused on patients with the blood disorder known as hereditary antithrombin deficiency. Those who received the protein recombinant human antithrombin reported no excessive clotting during treatment or seven days after treatment.
"This is a remarkable technologic feat," said study investigator Michael Paidas, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences, and director of the Women and Children's Center for Blood Disorders at Yale. "We've shown that this genetically engineered protein can prevent complications linked to antithrombin deficiency. Ours is the first team in the United States to use the protein in a clinical trial with pregnant patients."
Antithrombin occurs naturally in the body and acts as a blood thinner that signals when blood is clotting too much. Patients with antithrombin deficiency do not naturally produce antithrombin. Low antithrombin levels can result in excessive clotting, or venous thromboembolic events (VTEs), which can complicate childbirth and surgery. Those with the condition who undergo childbirth and/or surgical procedures are at high risk for pulmonary embolism-a major cause of maternal death.
The genetic deficiency affects approximately one in 2,000 to one in 5,000 people, and half of all people diagnosed suffer a thrombosis before age 25. The deficiency can also be acquired through ailments such as liver disease, malnutrition or severe burns, which can lead to impaired production of antithrombin.
Yale was one of only two U.S. sites to participate in the study, which included 18 patients-12 pregnant and six surgical. Participants with a history or risk of VTE were given an initial dose of recombinant human antithrombin, followed by maintenance doses based on antithrombin levels. The study also showed that new dosing methods could be tailored to individual patients, which helped pregnant patients to achieve and maintain ideal antithrombin levels.
If approved by the FDA, recombinant human antithrombin will be marketed under the brand name ATryn®; the compound was developed by GTC Biotherapeutics and licensed to Ovation Pharmaceuticals, Inc. in the U.S.
Yale University
Antithrombin occurs naturally in the body and acts as a blood thinner that signals when blood is clotting too much. Patients with antithrombin deficiency do not naturally produce antithrombin. Low antithrombin levels can result in excessive clotting, or venous thromboembolic events (VTEs), which can complicate childbirth and surgery. Those with the condition who undergo childbirth and/or surgical procedures are at high risk for pulmonary embolism-a major cause of maternal death.
The genetic deficiency affects approximately one in 2,000 to one in 5,000 people, and half of all people diagnosed suffer a thrombosis before age 25. The deficiency can also be acquired through ailments such as liver disease, malnutrition or severe burns, which can lead to impaired production of antithrombin.
Yale was one of only two U.S. sites to participate in the study, which included 18 patients-12 pregnant and six surgical. Participants with a history or risk of VTE were given an initial dose of recombinant human antithrombin, followed by maintenance doses based on antithrombin levels. The study also showed that new dosing methods could be tailored to individual patients, which helped pregnant patients to achieve and maintain ideal antithrombin levels.
If approved by the FDA, recombinant human antithrombin will be marketed under the brand name ATryn®; the compound was developed by GTC Biotherapeutics and licensed to Ovation Pharmaceuticals, Inc. in the U.S.
Yale University
Antithrombin Current Events and Antithrombin News RSSArterial, venous or total mesenteric ischemia/reperfusion causes different types of injury?
It is known that I/R induces an inflammatory response deleterious to the organ involved but also to the system as a whole.
The risk factors of abdominal venous thrombosis
Abdominal venous thrombosis may present as BCS or SVT. Hereditary and acquired risk factors have been implicated in the etiopathogenesis of abdominal venous thrombosis
Men at increased risk of death from pneumonia compared to women
Men who come to the hospital with pneumonia generally are sicker than women and have a higher risk of dying over the next year, despite aggressive medical care.
Pathway to cell death redefined in landmark study
A new study led by investigators from the University of Pittsburgh School of Medicine demonstrates that the process of necrosis, long thought to be a chaotic, irreversible pathway to cell death, may actually be triggered as part of a regulated response to stress by a powerful protein, SRP-6, that can potentially halt necrosis in its path.
Enoxaparin beats unfractionated heparin as adjunct therapy for heart attacks
A simple-to-use strategy that prevents blood clots in patients who have suffered a heart attack markedly reduces the risk of repeat heart attack or death when compared to an older, more widely used blood thinning strategy.
Dogs keep dying: Too many owners remain unaware of toxic dog food
Even though Diamond, Country Value and Professional brand dog foods have been recalled for containing highly toxic aflatoxins, they have caused at least 100 dog deaths in recent weeks, say Cornell University veterinarians, who are growing increasingly alarmed.
ESC Congress 2003: Prothrombotic mutations are associated with increased cardiovascular events in postmenopausal women receiving hormone replacement therapy
IMPORTANT: This press release accompanies a poster or oral session given at the ESC Congress 2003. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology Recent studies have suggested that hormone replacement therapy may be associated with an increased cardiovascular risk in postmenopausal women. This increased cardiovascular risk has been suggested to be related to a detrimental effect of estrogens and progestins on coagulation factors. Several studies have suggested that isolated genetic mutations of coagulation factors are associated with an increased risk of events in postmenopausal women with arteri
Intensive care treatment may be bad for your health
Two articles in the latest issue of Critical Care reveal how intensive care therapy may be beneficial in the short but not in the long term. Being treated in intensive care units may help critically ill patients survive but the quality of life - if they survive - is often severely impaired. It is unclear whether this impairment is a complication of the illness or a complication of therapy.
Study simulating aircraft conditions suggests increased risk of venous thrombosis (p 1657)
Two weeks after a study published in THE LANCET concluded that there was no increased risk of venous thrombosis from air travel (Kraaijenhagen RA, Haverkamp D. Travel and risk of venous thrombosis. Lancet 2000; 356: 1492-93), a research letter published in this week’s issue of THE LANCET suggests an increased risk of venous thrombosis in a study which involved the simulation of aircraft conditions. Aeroplane flights are thought to increase the risk of venous thrombosis, but the mechanism behind this effect is unknown. Suggested risk factors are a hypobaric (low pressure) and hypoxic (low oxygen) environment, sedentariness, and dehydration. Bj'¸rn Bendz and colleagues from Ullev'å
More Antithrombin Current Events and Antithrombin News Articles
|
The Role of Antithrombin and Thromboplastin (Thrombopalstic Substance) in the Coagulation of the Blood. by William Henry. HOWELL (Author) | |
 |
Antithrombin: Webster's Timeline History, 1942 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Antithrombin," including when used in literature (e.g. all authors that might have Antithrombin in their name). As such, this book represents the largest compilation of timeline events associated with Antithrombin when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social... |
 |
Biology of Antithrombins by Geza Sas (Author) This publication covers topics related to the biochemistry and clinical significance of the proteins displaying thrombin-inhibiting activity. Only in the past twenty-five years has the biological significance of proteins inhibiting blood coagulation been recognized. These inhibitors play a key role in the regulation of blood coagulation by controlling the activated serine proteinases. Certain proteins, the antithrombins, exert their effect upon thrombin leading to a reduction in the rate of fibrin formation. Important work has been done with thrombosis; chronic liver disease; disseminated intravascular coagulation; thromboembolic episodes during pregnancy, delivery; and oral contraceptive therapy. Substitution of purified, concentrated antithrombin III fractions has proven to be an... |
 |
Antithrombin Medical Guide by Qontro Medical Guides (Author) The Antithrombin Medical Guide is a publication which has been designed to better help readers understand Antithrombin. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Antithrombin. The Antithrombin Medical Guide is highly recommended for those interested in understanding and learning more about Antithrombin. |
|
Hypercoagubility tests: An entry from Thomson Gale's Gale Encyclopedia of Nursing and Allied Health by Linda D., B.A., PBT (ASCP) Jones (Author) The “Gale Encyclopedia of Nursing and Allied Health” is an alphabetically arranged five-volume set of more than 850 entries written for students and professionals in the field. Topics include body systems and functions, conditions and common diseases, issues and theories, techniques and practices, and devices and equipment. The Encyclopedia covers all major health professions, including nursing, physical therapy, occupational therapy, respiratory therapy, medical lab technology, emergency medical technology, dental assistance, pharmacology and nutrition, and features appendices of related organizations, agencies and associations. | |
|
Synthetic antithrombin agents by J. C Powers (Author) | |
|
The Role Antithrombin and Thromboplastin by William Henry HOWELL (Author) | |
|
The preparation and properties of thrombin, together with observations on antithrombin and prothrombin by William Henry Howell (Author) | |
|
Note on the effect of temperature upon the action of thrombin and antithrombin by William H Howell (Author) | |
|
The rôle of antithrombin and thromboplastin (thromboplastic substance) in the coagulation of blood by William H Howell (Author) |
| © 2009 BrightSurf.com |